Sheta, M. A. E. - S. A. E. - M., F. Zahran, A. A. A. elhady el Wahab, and A. M. Ashmawy,
MiRNAs-181a/b in Triple Negative breast cancer subtypes and response to chemotherapy,
, Giza, Zagazig univ, 2017.
AbstractSpotting the scope on triple-negative breast cancer (TNBC) as the most aggressive type of breast cancer, with no targeted therapeutic options. TNBC is often characterized by having defects in DNA repair pathway making this cancer a rational target for the Doxorubicin as a chemotherapeutic agent, and for the synthetic lethality of olaparib as an inhibitory target agent of the alternative DNA repair pathway (poly ADP-ribose polymerase “PARP” inhibitor). The present study aims to evaluate the value of miRNAs-181a/b as potential biomarkers in predicting the response of TNBC to therapy. MiRNAs-181a/b expression was knocked down via transfection with anti-miRNAs-181a/b into MDA-MB-231 cell line using HiPerFect transfection reagent, the transfected and untransfected cells were subjected to doxorubicin and olaparib separately. Essential proteins involved in apoptosis and cell proliferation including Caspase-8, Bcl-2, and Ki-67 has been detected. Further, the expression level of ataxia telangiectasia mutated (ATM) was determined as a functional target of miRNAs-181a/b. A significant decrease in Caspase-8 activity, and Bcl-2, and a significant increase in cell survival, cell proliferation, and ATM protein were observed upon suppression of miRNAs-181a/b by their inhibitors followed by treatment with eithr doxorubicin or olaparib for TNBC cell line (MDA-MB-231 cells). Collectively, our data confirmed that miRNA-181a and miRNA-181b play a critical role for detecting the sensitivity of TNBC cells to treatment. As well as miRNAs-181a/b could be used as predictive biomarkers for response to therapy.
Hamed, H., A. Hassanin, A. Zaazaa, and M. Fawzy,
A new technique, compined plication incision (CPI), for correction of penile curvature,
, Cairo, Cairo University, 2016.